Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.  LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations.  EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.  TitleLead AuthorPresentation detailsLUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.

 

James Chih-Hsin Yang, MD, PhD

 

 

 

Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT

 

 

 "We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the bo
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)...  (Booth #7309, North Hall) — Dicom Systems ... DCMSYS Interface WebBridge, at the 100th annual RSNA Meeting ... Chicago, Illinois . ... for medical facilities of any size, WebBridge allows any ... non-standard data (e.g. JPEG, TFF, PDF, TXT, etc.) to ...
(Date:11/27/2014)... 2014 Hovione announced today it ... with the U.S. Food and Drug Administration (FDA). This ... improved drug delivery options for established drugs. ... formulation using a new patented crystalline base form of ... prescribed oral antibiotics for acne. Currently, there are no ...
(Date:11/26/2014)... 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... "Quality Affordable Healthcare Products®," today announced the closing of ... sale of 6,809,210 ordinary shares at a public offering ... of the option to purchase up to an additional ... Barclays Capital Inc., as representatives of the several underwriters. ...
Breaking Medicine Technology:Dicom Systems Announces WebBridge Interface at RSNA 2014 2Hovione Files its First Investigational New Drug Application With the FDA 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4
... the Potential Utility of Modigene,s CTP Technology ... ... Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: MODG) today reported ... journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s carboxyl terminal peptide ...
... 24 Iodine has been used as an,antimicrobial ... about molecular,iodine yet many women suffering from Fibrocystic ... may soon yield an effective,nonhormonal treatment. While ... market, all,available hormonal therapies have significant adverse events. ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:11/28/2014)... Novatus, a leading provider of ... which provides customers with greater reporting capabilities, more ... “As we continue to evolve and grow the ... and improved performance in response to requests from ... “With the enhancements that we have made to ...
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently ... Dr. Jeffrey Epstein is excited to offer patients ... platform, the site is uniquely designed for easing viewing ... 75% of all prospective rhinoplasty patients research upcoming procedures ... on with smartphones, tablets, and laptops, as well as ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PA (PRWEB) November 28, 2014 An inventor ... curing light on a patient’s filling and it was almost ... more ergonomic curing light," she said. , The patent-pending Access ... It eases access to areas of the mouth, as well ... promotes efficiency and safety. Easy to use and clean, it ...
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2
... cancer surgeons regularly confer with plastic surgeons prior to surgery, ... a new study led by researchers at the University of ... breast cancer treatment can vary widely ranging from small ... the type of care a woman receives when it comes ...
... ,PHOENIX, Ariz. Aug. 31, 2010 The first study ... how they affect cell growth has identified two potential anti-cancer ... Genomics Research Institute (TGen) published this month in the journal ... aggressive cancer lesions that occur most frequently in the bones ...
... exposed to violence in their community are at an increased ... asthma or any cause, according to new research from the ... violence has been linked to more symptoms in pediatric asthma ... a longitudinal study showing a connection in an adult population ...
... cancer deaths worldwide, and the prognosis is generally poor, ... one type of lung cancer, adenocarcinoma, has been increasing ... in tumor cell biology that result in a more ... tissue) that have been completely surgically removed may help ...
... Portugal: Hundreds of millions of euros are being ... consulting community pharmacists rather than going straight to their ... 1 September) at the annual conference of the International ... million was freed up in one year for other ...
... Selenium effects may vary according to individual,s characteristics. ... cancer. According to results of a study published ... Prevention , a journal of the American Association for Cancer ... cancer. "The lower the levels of selenium, the ...
Cached Medicine News:Health News:Surgeons impact whether a woman gets breast reconstruction, U-M study finds 2Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:Violence in inner city neighborhoods contributes to trouble with asthma 2Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Health advice from pharmacists saves hundreds of millions of euros 2Health News:Health advice from pharmacists saves hundreds of millions of euros 3Health News:Increasing selenium intake may decrease bladder cancer risk 2
The new BioZ Dx incorporates the world's most advanced impedance cardiography (ICG) technology and powerful reporting features to quickly and easily provide noninvasive hemodynamic parameters....
... Implant is an endoscopic urethral implant ... (SUI). Upon implantation, the Tegress™ Implant ... (EVOH) in a Dimethyl Sulfoxide (DMSO) ... that reinforces the integrity of the ...
... reproducible re-entry of a guidewire from the ... of a peripheral vessel., , Locate ... facilitates rapid and accurate orientation of the ... eliminates the need for additional equipment, , ...
... system is intended for the qualitative detection ... When performed according to these instructions, the ... clinical information, may aid in the determination ... diagnosis of VZV infections. This test is ...
Medicine Products: